Medication Monitor



Generic Name (Trade Name—Company)
Notes
June 24, 2011

Romidepsin

(Istodax—Celgene)
Treatment of peripheral T-cell lymphoma

Uses:

Treatment of peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior therapy 

According to a press release by Celgene, FDA approval of romidepsin was based on data from two studies demonstrating an improved response rate in patients with PTCL. Improvements in hard clinical outcomes, such as improvement in overall survival, have not been demonstrated. Romidespin was previously approved for treatment of cutaneous T-cell lymphoma in patients who have received at least one prior systemic therapy.